ReviewMagyar onkologia2025
[Recent advances in the systemic treatment of head and neck cancers].
Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) remains a malignancy with high global morbidity and mortality. Over the past decade, systemic treatment paradigms for recurrent/ metastatic (R/M) HNSCC have evolved significantly with the introduction of immuno- and targeted therapies. The phase III KEYNOTE-048 trial established pembrolizumab, alone or in combination with chemotherapy, as a new firstline standard in PD-L1 positive cases. In the second-line setting, the CheckMate 141 and KEYNOTE-040 trials confirmed the survival benefit and favorable safety profile of PD-1 inhibitors. The recent KEYNOTE-689 and NIVOPOSTOP studies highlight the potential role of perioperative and adjuvant immunotherapy in resectable, locally advanced HNSCC. However, multiple negative studies underscore the limitations of immune checkpoint inhibitors in the definitive treatment of locally advanced disease. Defining the optimal sequencing of systemic therapies remains a key clinical challenge in this patient population.
Indexed as
Identifiers
40643452PMC12255508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.